EGFR (d746)

EGFR · Variant type: point · HGVS: p.d746

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	99.6%	0.4%	97.24
2	Mobocertinib	99.5%	0.5%	97.22
3	Erlotinib	99.5%	0.5%	99.75
4	Lazertinib	99.5%	0.5%	97.47
5	Canertinib	99.5%	0.5%	96.49
6	Neratinib	99.0%	1.0%	93.18
7	Vandetanib	98.9%	1.1%	95.74
8	Afatinib	98.6%	1.4%	98.50
9	Gefitinib	98.2%	1.8%	99.25
10	Brigatinib	97.7%	2.3%	82.96
11	Pralsetinib	95.5%	4.5%	93.43
12	Bosutinib	95.1%	4.9%	87.22
13	Ibrutinib	94.4%	5.6%	94.74
14	Dacomitinib	94.2%	5.8%	97.99
15	Lapatinib	89.1%	10.9%	99.25
16	Dasatinib	84.7%	15.3%	87.97
17	Alectinib	76.5%	23.5%	95.49
18	Pacritinib	72.3%	27.7%	88.64
19	Ponatinib	71.8%	28.3%	78.23
20	Fostamatinib	68.8%	31.2%	96.74
21	Capmatinib	57.1%	42.9%	99.75
22	Gilteritinib	50.2%	49.8%	88.97
23	Defactinib	32.8%	67.2%	92.68
24	Alpelisib	31.4%	68.6%	97.22
25	Ceritinib	24.7%	75.3%	95.44

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	99.6%	99.1%	+0.5%
Mobocertinib	99.5%	100.0%	-0.5%
Erlotinib	99.5%	99.4%	+0.1%
Lazertinib	99.5%	100.0%	-0.5%
Canertinib	99.5%	98.4%	+1.0%
Neratinib	99.0%	100.0%	-1.0%
Vandetanib	98.9%	99.3%	-0.5%
Afatinib	98.6%	100.0%	-1.4%
Gefitinib	98.2%	99.9%	-1.7%
Brigatinib	97.7%	98.5%	-0.7%
Pralsetinib	95.5%	99.1%	-3.6%
Bosutinib	95.1%	99.3%	-4.2%
Ibrutinib	94.4%	99.3%	-5.0%
Dacomitinib	94.2%	99.8%	-5.6%
Lapatinib	89.1%	99.2%	-10.0%
Dasatinib	84.7%	97.9%	-13.2%
Alectinib	76.5%	—	—
Pacritinib	72.3%	—	—
Ponatinib	71.8%	—	—
Fostamatinib	68.8%	97.8%	-28.9%
Capmatinib	57.1%	—	—
Gilteritinib	50.2%	91.0%	-40.8%
Defactinib	32.8%	94.6%	-61.8%
Alpelisib	31.4%	—	—
Ceritinib	24.7%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 27.7ms